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On admission, the patient’s fever was
still high (40°C), there was severe
hypoxemia with bilateral diffuse pulmo-
nary infiltrates, a tachyarrhythmia with
auricular fibrillation and gallop, and con-
junctival injection. Laboratory results
indicated mild renal insufficiency (urea
12.5 mmol/L; creatininemia 180 µmol/
L), hepatic cytolysis (serum glutamic-
oxaloacetic transaminase 236 and serum
glutamic-pyruvic transaminase 72), a
moderate thrombocytopenia (platelet
counts 86 000/mm3), an inflammatory
syndrome (C-reactive protein 272 mg/L),
and a capillary leak syndrome (hemat-
ocrit 49%; albuminemia 20 g/L). On the
night after admission, an aggravation of
the cardiac function with myocarditis
developed; it responded quickly to symp-
tomatic treatment. The patient’s condi-
tion improved steadily on the following
days with a reduction of the pulmonary
manifestations, and he was discharged
on April 2.
Blood samples obtained on March 21
and March 29 were tested for the pres-
ence of antibodies to hantaviruses (Puu-
mala,  Hantaan,  Sin Nombre, [SNV]
Seoul, and Laguna Negra) by immuno-
globulin (Ig) M-capture and IgG
enzyme-linked immunosorbent assay.
IgM antibodies were detected for all
these antigens on the first sample, but
there was no increase on the second sam-
ple. A substantial increase in IgG titer for
SNV  and Laguna Negra antigens was
observed from the first to the second
sample, but not for the other antigens.
The virus could not be detected either by
reverse transcription-polymerase chain
reaction or by inoculation into cell cul-
ture (three passages). Since the identifi-
cation in 1993 of SNV as the cause of
HPS (1), numerous cases of this disease
have been confirmed in various regions
of North and South America. The first
HPS cases associated with Andes virus in
Argentina (2) were observed in 1995.
Since then, more than 500 HPS cases
have been reported in six countries of
South America (Argentina, Bolivia, Bra-
zil, Chile, Paraguay, and Uruguay), with
mortality rates ranging from 30% to
70%.
Hantaviruses are rodent-borne, and
each is associated with a specific rodent.
Sigmodontine rodents are the vectors of
hantaviruses associated with HPS. Infec-
tions are most frequently transmitted by
inhalation of virus-contaminated aero-
sols of rodent excreta, but human-to-
human transmission has also been
described (3).
The patient described here was prob-
ably infected in Chile and more likely in
the Puerto Monte area, where HPS cases
were reported in 2001. Unfortunately,
virus could not be detected because the
first blood sample was obtained 2 weeks
after onset of fever.
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Efficacy of Interferon
Alpha-2b and Ribavirin
against West Nile
Virus In Vitro
To the Editor:  West Nile virus
(WNV) infected humans in the Western
Hemisphere for the first time in the late
summer of 1999. During 1999 and 2000,
nine deaths occurred among 80 patients
with meningitis or encephalitis in New
York City; Westchester County, New
York; New Jersey; and Connecticut (1-
3). Effective antiviral agents are
unknown for infections caused by WNV.
Odelola (4) described 83% survival of
WNV-infected mice and eradication of
virus from brain when 1.5 mg. of ribavi-
rin was administered by intraperitoneal
injection after virus inoculation. Survival
of controls was 25%. More recently, Jor-
dan et al. have reported inhibition of
WNV by a relatively high concentration
of ribavirin (200 mM) given after infec-
tion of human oligodendroglial cells in
vitro (5). Shahar et al. (6) reported pro-
tection of fetal mouse spinal cord tissues
with mouse alpha and beta interferon
before inoculation with WNV. We tested
human recombinant interferon alpha-2b
and ribavirin for activity against WNV
in a primate cell system similar to that
used to measure the effect of these
agents on Bovine viral diarrhea virus, a
cultivatable, closely related surrogate for
Hepatitis C virus.Vero cells were cul-
tured at 37o and 5% CO2 in a 96-well
microtiter plate. Approximately 13,000
cells were seeded in each well 24 hours
before specific concentrations of ribavi-
rin or interferon alpha-2b were added.
Approximately 2.5 X 103 PFU of WNV
isolated from  Culex pipiens (7) was
added 1.5-2 hours after or before the
addition of interferon alpha-2b or ribavi-
rin to Vero cells. Forty-four hours after
treatment, a colorimetric proliferation
assay was used to measure viable cells in
each treated well according to the proto-
col of Promega (Madison, WI). Cells
exposed to specific concentrations of
antiviral compounds, but without WNV,
were used as negative controls.
 Interferon alpha-2b was protective
and therapeutic. Interferon alpha-2b
inhibited viral cytotoxicity at low dosage
when applied before or after infection of
cells with WNV. For example, viral pro-
tection was observed from 3,000 U/mL
to 188 U/mL 2 hours before infection of
cells with WNV. Interferon alpha-2b
was also therapeutic when applied after
cells were infected with WNV. Virus-
induced cytotoxicity was inhibited by
concentrations of  >5.9 U/mL when
added 1.5 hours after infection (Figure).
The optical density 490 values in these
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comparison test) when compared with
the uninfected cells.
Ribavirin was protective but not
therapeutic in vitro. Cells were protected
at dosages of 400 and 500 mM but not at
dosages of <300 mM of ribavirin applied
2 hours before infection of cells with
WNV. A cytotoxic effect of ribavirin
occurred at concentrations of 600-1,000
mM.
In humans, daily doses of 3 million
units of interferon result in serum levels
of 10-20 U/mL, well above that required
for in vitro efficacy (8). In contrast, oral
ribavirin doses of 2,400 mg daily yield a
steady-state serum concentration of 3-4
mg/mL after several days, approxi-
mately 12-40-fold less than the in vitro
inhibitory concentrations of 200-500 mM
(50-125 mg/mL) noted by Jordan et al.
(5) and in this study. Intravenous admin-
istration of 4 g daily, as used in the treat-
ment of Lassa fever, would be required
to reach a potentially effective serum
concentration (9,10). However, intracel-
lular accumulation and phosphorylation
of ribavirin may account for its therapeu-
tic effect in mice (4).
We conclude that interferon alpha-2b
possesses greater therapeutic activity in
vitro than ribavirin, with a potentially
greater therapeutic ratio in humans.
Whether combination therapy, as
employed against hepatitis C, may be
optimal requires further study.
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Figure. Effect of varying concentrations of interferon a-2b (FN) on West Nile virus-infected Vero
cells. The vertical axis represents a colorimetric assay of cellular lactic  dehydrogenase, which is
directly proportional to cell viability and proliferation.  OD = optical density. 
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